Cargando…
Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
INTRODUCTION: Immune checkpoint inhibitors (ICIs) are effective in the treatment of advanced esophageal squamous cell carcinoma (ESCC); however, their efficacy in locally advanced resectable ESCC and the potential predictive biomarkers have limited data. METHODS: In this study, locally advanced rese...
Autores principales: | He, Wenwu, Leng, Xuefeng, Mao, Tianqin, Luo, Xi, Zhou, Lingxiao, Yan, Jiaxin, Peng, Lin, Fang, Qiang, Liu, Guangyuan, Wei, Xing, Wang, Kangning, Wang, Chenghao, Zhang, Sha, Zhang, Xudong, Shen, Xudong, Huang, Depei, Yi, Huan, Bei, Ting, She, Xueke, Xiao, Wenguang, Han, Yongtao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842349/ https://www.ncbi.nlm.nih.gov/pubmed/35305102 http://dx.doi.org/10.1093/oncolo/oyab011 |
Ejemplares similares
-
A Highly Active and Tolerable Neoadjuvant Regimen Combining Paclitaxel, Carboplatin, 5-FU, and Radiation Therapy in Patients with Stage II and III Esophageal Cancer
por: van de Schoot, L., et al.
Publicado: (2007) -
Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022) -
Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study
por: Jiang, Li, et al.
Publicado: (2022) -
Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy
por: He, Wenwu, et al.
Publicado: (2021) -
Correction to: Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study
por: Jiang, Li, et al.
Publicado: (2023)